XML 37 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Data
 3 Months Ended
Mar. 30, 2018
Segment Reporting [Abstract]  
Segment Data
19.
Segment Data
The Company's continuing operations are limited to the results of operations from the Specialty Brands segment as the Specialty Generics Disposal Group is reported as a discontinued operation. See Note 4 for further details on the Specialty Generics Disposal Group. Selected information for the reportable segment is as follows:

Three Months Ended

March 30,
2018
 
March 31,
2017
Net sales:
 
 
 
Specialty Brands
$
572.6

 
$
560.0

Operating income:
 
 
 
Specialty Brands
$
240.3

 
$
267.0

Unallocated amounts:
 
 
 
Corporate and unallocated expenses (1)          
(43.7
)
 
0.4

Intangible asset amortization
(176.3
)
 
(169.8
)
Restructuring and related charges, net (2)
(23.1
)
 
(11.3
)
Operating income
$
(2.8
)
 
$
86.3


(1)
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segment.
(2)
Includes restructuring-related accelerated depreciation.

Net sales by product family within the Company's reportable segment is as follows:
 
Three Months Ended
 
March 30,
2018
 
March 31,
2017
H.P. Acthar Gel
$
243.8

 
$
271.8

Inomax
139.8

 
128.4

Ofirmev
82.0

 
73.4

Therakos
57.4

 
51.2

Amitiza (1)
23.0

 
—

BioVectra
10.5

 
9.9

Other
16.1

 
25.3

Net sales
$
572.6

 
$
560.0


(1) Amitiza net sales consist of both product and royalty net sales. Refer to Note 3 for further details on Amitiza's revenues.